A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

Key facts

Sponsor

Genmab

Principal Investigator

ABBVIE INC.

AbbVie

Intervention

Epcoritamab(drug)

Enrollment

184 enrolled

Eligibility

18 years · All sexes

Timeline

2022 – 2027

Study locations (30)

• Infirmary Health - Infirmary Cancer Care at Mobile Infirmary /ID# 264630, Mobile, Alabama, United States
• University of Arkansas for Medical Sciences /ID# 244562, Little Rock, Arkansas, United States
• Highlands Oncology Group, PA /ID# 245002, Springdale, Arkansas, United States
• Beverly Hills Cancer Center /ID# 255327, Beverly Hills, California, United States
• Compassionate Cancer Care Research Group - Fountain Valley /ID# 246133, Fountain Valley, California, United States
• UCSF Fresno /ID# 263286, Fresno, California, United States
• University of California, Los Angeles /ID# 244573, Los Angeles, California, United States
• Rocky Mountain Cancer Centers - Boulder /ID# 247653, Boulder, Colorado, United States
• Bennett Cancer Center - Stamford Hospital /ID# 244530, Stamford, Connecticut, United States
• MedStar Washington Hospital Center /ID# 246068, Washington D.C., District of Columbia, United States
• Cancer Specialists of North Florida /ID# 261842, Jacksonville, Florida, United States
• Florida Cancer Specialists /ID# 260854, Lake Mary, Florida, United States
• Mount Sinai Medical Center-Miami Beach /ID# 249045, Miami Beach, Florida, United States
• Memorial Hospital West /ID# 248432, Pembroke Pines, Florida, United States
• BRCR Medical Center Inc /ID# 262527, Tamarac, Florida, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

AbbVie

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Diffuse large B-cell lymphoma with chronic inflammation

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE2NCT07538180
  Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCL
  Sun Yat-sen University
• RECRUITINGNCT07070648
  Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET
  Fudan University
• RECRUITINGPHASE1, PHASE2NCT06829771
  Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
  Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• RECRUITINGPHASE3NCT06717347
  A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
  Merck Sharp & Dohme LLC
• RECRUITINGPHASE2NCT06687772
  CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
  Washington University School of Medicine
• RECRUITINGPHASE1, PHASE2NCT06760039
  Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
  Sun Yat-sen University
• RECRUITINGPHASE2NCT06701357
  CR-CHOP+X in Previously Untreated DEL
  Ruijin Hospital
• RECRUITINGPHASE2NCT06664411
  Pola-ZR2P in Previously Untreated DLBCL
  Navy General Hospital, Beijing

See all trials for Diffuse large B-cell lymphoma with chronic inflammation →